Novocure reports quality‑of‑life and pain benefits from PANOVA‑3 trial of TTFields in pancreatic cancer
Novocure announced that a prespecified secondary analysis of its Phase 3 PANOVA‑3 trial showed statistically significant improvements in quality of life and pain outcomes for patients with unresectable, locally advanced pancreatic adenocarcinoma treated with Tumor Treating Fields plus chemotherapy. The trial had already met its primary endpoint by demonstrating a significant increase in median overall survival versus chemotherapy alone. The company said the therapy was well‑tolerated with no new safety signals.
Why it matters
The positive secondary‑endpoint data may strengthen clinicians’ and payers’ confidence in the TTFields therapy, potentially supporting broader adoption and revenue growth for Novocure.
Key facts
- 1The PANOVA‑3 trial met its primary endpoint, showing a statistically significant improvement in median overall survival for patients receiving TTFields therapy with gemcitabine and nab‑paclitaxel. finanznachrichten.de
- 2Prespecified secondary analyses demonstrated statistically significant and clinically meaningful benefits on multiple quality‑of‑life and pain measures. finanznachrichten.de
- 3TTFields therapy was well‑tolerated in the trial, with no new safety signals observed and mild to moderate skin adverse events being the most common device‑related events. finanznachrichten.de
- 4The trial evaluated TTFields therapy combined with gemcitabine and nab‑paclitaxel versus gemcitabine and nab‑paclitaxel alone in patients with unresectable, locally advanced pancreatic adenocarcinoma. finanznachrichten.de
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.